Opko Health, Inc.
Opko Health, Inc. (OPK) is a diversified healthcare company operating across pharmaceuticals and diagnostics. It develops and commercialises therapeutics while also offering clinical laboratory services and diagnostic products. For investors, key points are its reliance on a mix of product revenues, diagnostic testing income and potential milestone or licensing payments tied to its pipeline and partnerships. Like many small‑cap healthcare companies, Opko’s outlook is shaped by clinical trial progress, regulatory decisions and competitive dynamics. Financial performance can be volatile and the company may require additional capital, which can dilute shareholders. Investors should weigh the potential upside from successful drug or diagnostic launches against patent, regulatory and execution risks. This summary is for general educational purposes only and is not personalised investment advice; investors should consider their objectives and consult a qualified financial adviser before acting.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Opko Health's stock with a target price of $4.25, indicating potential growth.
Financial Health
Opko Health is generating decent revenue and cash flow, but its profitability is relatively low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring OPK
Walgreens' Restructuring: A New Healthcare Landscape
Following its $10 billion acquisition by Sycamore Partners, Walgreens is going private and splitting into five separate companies. This major restructuring of a key industry player could create significant opportunities for competitors and specialized healthcare service providers to capture market share.
Published: August 29, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Milestones Ahead
Clinical and regulatory milestones can materially affect value, offering upside if successful — though outcomes are uncertain and timing can vary.
Diagnostics Revenue Stream
Diagnostic testing and lab services provide recurring revenue diversity, but volumes can fluctuate with market demand and reimbursement changes.
Capital & Dilution
Small‑cap healthcare firms may need additional funding to advance programmes, which can dilute shareholders; review the balance sheet carefully.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
